Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Cetuximab and docetaxal for squamous cell cancer of the head and neck, from ASCO 2008

2009 ASCO Annual Meeting

29 May - 2 Jun 2009

Published: 27 Nov 2008

Views: 16297

Rating:

Save

Professor Jan B. Vermorken

Categories:
Head & neck

Related Videos

Choosing wisely: Head and neck cancer

Dr Kumar Prabhash - Tata memorial hospital, Mumbai, India

Choosing wisely: Head and neck cancer ( Dr Kumar Prabhash - Tata memorial hospital, Mumbai, India )

Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for...

Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland

Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN ( Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland )

Intraoperative Radiotherapy

Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal

Intraoperative Radiotherapy ( Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal )

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first...

Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC ( Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia )

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally...

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )

Low-dose nivolumab leads to improved overall survival for head and neck cancer...

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Low-dose nivolumab leads to improved overall survival for head and neck cancer patients ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

RAGNAR study evidences efficacy and safety of erdafitinib in patients with...

Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France

RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malignancies ( Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France )

ASCO 2022: Head and neck cancer highlights

Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA

ASCO 2022: Head and neck cancer highlights ( Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA )

Avasopasem produces significant improvement of severe oral mucositis in head...

Dr Carryn Anderson - University of Texas Medical Branch, Texas, USA

Avasopasem produces significant improvement of severe oral mucositis in head and neck patients ( Dr Carryn Anderson - University of Texas Medical Branch, Texas, USA )

More from ecancer